08:00 AM EDT, 09/10/2025 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Wednesday it filed a request for regulatory clearance to launch a phase 1/2a clinical trial of ARO-MAPT for the potential treatment of tauopathies, including Alzheimer's disease.

The application was submitted to the New Zealand Medicines and Medical Devices Safety Authority for review by the standing committee on therapeutic trials, the company said.

Pending clearance, the company plans to proceed with a phase 1/2a placebo-controlled dose-escalating study of ARO-MAPT in up to 64 healthy subjects and up to 48 subjects with early Alzheimer's disease, Arrowhead said.